Factors that affect the development of acute hemorrhagic rectal ulcer syndrome and rebleeding

Natsumi Uehara1,2 | Kazuaki Inoue3 | Yuichiro Kuroki4 | Naoki Miyao2 | Kenta Iwahashi5 | Reika Suzuki2 | Toshiyuki Endo2 | Kunio Asonuma2 | Erika Yoshida2 | Naoko Koshibu2 | Akihiro Tabuchi2 | Misako Tohata2 | Shotaro Hanamura6 | Kuniyo Gomi2 | Yorimasa Yamamoto2 | Masatsugu Nagahama2

1Department of Gastroenterology, Medical Topia Soka Hospital, Saitama, Japan
2Department of Gastroenterology, Showa University Fujigaoka Hospital, Kanagawa, Japan
3Department of Gastroenterology, International University of Health and Welfare Narita Hospital, Chiba, Japan
4Department of Gastroenterology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Kanagawa, Japan
5Department of Internal medicine, Honda Hospital, Tokyo, Japan
6Department of Gastroenterology, Kikuna Memorial Hospital, Kanagawa, Japan

Correspondence
Natsumi Uehara, Medical Topia Soka Hospital, 1-11-18, Yatsuka, Soka-shi, Saitama, 340-0028, Japan.
Email: natsumi_uehara@med.miyazaki-u.ac.jp

Abstract
Objectives: Acute hemorrhagic rectal ulcer syndrome (AHRUS) causes massive bleeding and often recurrent rebleeding from rectal ulcers that form immediately above the dentate line. This study aimed to determine the clinical background and risk factors contributing to rebleeding in patients with AHRUS and the most appropriate method of hemostasis treatment.

Methods: This retrospective study included 93 patients diagnosed with AHRUS at Showa University Fujigaoka Hospital, Japan, between April 2009 and November 2018. Information on clinical background factors, endoscopic findings, and hemostasis was obtained from medical records. The relationship with episodes of rebleeding was analyzed by multivariate logistic regression analysis.

Results: The median age was 79 years, and 84 patients (90%) had a performance status of grade 2 or higher. The patients had multiple background factors, with a median number of 5 per patient. The background factors could be classified into two major factors: those related to arteriosclerosis and those related to delayed wound healing.

In the multivariate analysis, significantly more rebleeding occurred in patients with active bleeding during the initial endoscopy (odds ratio 4.88, 95% confidence interval 1.80–14.46, p = 0.003); significantly less rebleeding occurred in patients for whom hemostasis was first performed by clipping (odds ratio 0.30, 95% confidence interval 0.09–0.88, p = 0.035).

Conclusions: In bedridden older individuals with poor general health, multiple combinations of arteriosclerosis-related factors and protracted wound healing factors can induce AHRUS. We strongly recommend performing hemostasis via the clipping method on suspected bleeding points, including active bleeding sites, in AHRUS.

KEYWORDS
endoscopy, hemorrhage, hemostasis, rectum, ulcer
INTRODUCTION

Acute hemorrhagic rectal ulcer syndrome (AHRUS) is characterized by massive bleeding from the rectum in older patients with comorbidities. It was first reported by Kono et al. in 1980.1 Hirooka established the clinical entity of AHRUS based on his experience gained from treating 10 patients in 1984.2 This disease is characterized by the sudden onset of painless but extensive bleeding from rectal ulcers located at the distal rectum, directly above the dentate line, in patients suffering from severe comorbidities.3

There have been many reports of AHRUS in Japan3–6 and some recent reports from other Asian countries.7–9 Rectal bleeding from a Dieulafoy lesion has been reported in studies from western countries.10,11 A significant degree of variability exists in the number of reported AHRUS cases worldwide; these discrepancies may depend on how widely this clinical entity is recognized.

In 1997, Nakamura et al. analyzed 50 cases and observed that arteriosclerosis and a bedridden state were closely related to AHRUS5; no other associated factors were reported. AHRUS is also associated with high rebleeding rates (24%–50%)12–16 and mortality (20%–47.2%) following its onset.12,16 Although it is concerning that the general condition of patients with AHRUS worsens due to repeated bleeding, no studies have been conducted to determine the most appropriate endoscopic hemostatic method. Therefore, in this study, we aimed to identify the clinical background and risk factors associated with rebleeding and determine the most appropriate method of hemostasis for AHRUS treatment.

METHODS

Position of AHRUS at Showa University Fujigaoka Hospital, Japan

Approximately 10,000 endoscopic examinations are conducted annually at Showa University Fujigaoka Hospital, an acute care general hospital in Japan. From April 2009 to October 2018, there were 611 emergency endoscopic examinations for lower gastrointestinal bleeding conducted here, of which 136 (22%) were caused by AHRUS (Figure 1a). During the same period, 94 patients were diagnosed with AHRUS at the hospital; this number generally increased over time (Figure 1b).

Participants

Ninety-four patients were diagnosed with AHRUS at the hospital between April 2009 and October 2018; 93 were included in this study, and one was excluded due to missing data. We retrospectively analyzed the patients’ medical records and endoscopic files.

Survey items

We examined clinical background factors, lesion factors, and therapeutic factors. We extracted the background factors: gender, age, bedridden state, antithrombotic therapy, cardiac disease, infection, diabetes mellitus, cerebrovascular disease, on dialysis, cancer, fracture, hypoalbuminemia, and corticosteroid usage. All parameters were evaluated based on the data obtained immediately before onset.

We targeted lesion findings and endoscopic treatment at the time of initial endoscopy performed within 24 hours of the onset of bloody stool. Currently, there has been no established classification by lesion type of AHRUS. However, endoscopic findings have classified the lesions as circumferential ulcers, geographic-shaped ulcers, round ulcers, and Dieulafoy lesions.2,17,18 In this study, the endoscopic findings were simplified based on the lesion activity and simplified morphology, as emergency endoscopy did not always provide sufficient observations. Therefore, the activity was classified based on the presence or absence of active bleeding (Figure 2a), and the morphology was classified as an ulcer floor-forming lesion (Figure 2b) or a Dieulafoy lesion (Figure 2c).

Therapeutic factors were classified as follows: clipping method (CLIP), electrocoagulation with single-use electrosurgical hemostatic forceps (EC), argon plasma coagulation, endoscopic band ligation, or combinations of CLIP and EC methods. The definition of each factor is presented in Table 1. Rebleeding was defined as new bleeding requiring endoscopy within 30 days of the last bleeding, after which it was counted as a new case.

Statistical analysis

All statistical analyses were performed using R Commander (John Fox; McMaster University, Hamilton, Ontario, Canada), a graphical user interface for the R software environment (The R Foundation for Statistical Computing, Vienna, Austria). This analysis was conducted to identify the independent risk factors for rebleeding with AHRUS. Fisher’s exact test was used for the univariate analysis. In the multivariate analysis, we excluded factors with values below 10 and those that showed multicollinearity according to the Akaike information criterion, after which logistic regression analysis was performed.
FIGURE 1  
Acute hemorrhagic rectal ulcer syndrome (AHRUS) at the Showa University Fujigaoka Hospital from April 2009 to October 2018. (a) Among the diagnoses based on the 611 emergency colonoscopies for lower gastrointestinal bleeding, 136 (22%) were AHRUS, the second most common cause of bleeding. (b) Annual trends in the number of AHRUS patients; although there are variations, the trend was broadly increasing. Abbreviation: OGIB, obscure gastrointestinal bleeding.

FIGURE 2  
Case endoscopic photographs of lesion morphology of acute hemorrhagic rectal ulcer syndrome. (a) A case of active bleeding. (b) A case of an ulcer floor-forming lesion. (c) A case of a Dieulafoy lesion.

Research ethics

After the institutional review board of Showa University approved this study (approval number: F2018C79), information on the research, including the purpose of materials and information use, was disclosed to the research participants. In addition, an opt-out document was published on the portal website for clinical research; it was announced that the data would not be used if requested by the research participants.

RESULTS

All patients had comorbid AHRUS while hospitalized to treat their primary disease. Of the 93 patients included, 31 (33%) experienced rebleeding more than once. The highest frequency of rebleeding was 14 episodes in one patient (Figure 3). The survival prognosis for 30-day mortality was 15.0% (14 cases), and 60-day mortality was 17.2% (16 cases). In one patient, the direct cause of death was bleeding from AHRUS, whereas death was due to the primary disease in the remaining 15 patients.

FIGURE 3  
The number of rebleeding episodes per case. Of the 93 cases, 31 (33%) experienced rebleeding episodes more than once.

Clinical background factors

The male-to-female ratio was 1.16:1, and the median age was 79 years (interquartile range [IQR] 51–83 years). Eighty-four patients (90%) were bedridden, 53
## Definitions of patients’ backgrounds, lesions, and therapeutic factors

| Clinical background factors                                      | Description                                                                 |
|------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Bedridden state                                                  | Bedridden for more than half a day, equivalent to the performance status (PS; Eastern Cooperative Oncology Group, USA) of grade 2 or higher |
| Antithrombotic therapy                                           | Administration of anticoagulants or/and antiplatelet drugs                    |
| Cardiac disease                                                  | Heart failure, valvular disease, arrhythmia, and ischemic heart disease      |
| Infection                                                        | Infections requiring therapeutic intervention                                 |
| Diabetes mellitus                                                | Diabetes requiring therapeutic intervention                                   |
| Cerebrovascular disease                                          | Symptomatic cerebrovascular disease                                          |
| On dialysis                                                      | Patients on dialysis (any dialysis method)                                   |
| Cancer                                                           | Not cured cancer regardless of the treatment and stage                       |
| Fracture                                                         | Fracture causing instrumental activities of daily living disability         |
| Hypoalbuminemia                                                  | Serum albumin concentration below 2 g/ml                                     |
| Corticosteroid usage                                             | Regular or intermittent use of corticosteroids                               |

| Lesion factors                                                   | Description                                                                 |
|------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Active bleeding                                                  | Active bleeding at the initial endoscopic examination                       |
| Dieulafoy lesion (D)                                             | Dieulafoy ulcer (abnormally large, exposed vessels with small shallow ulcers or vascular lesion (no ulcers but only exposed blood vessels) |
| Ulcer floor-forming lesion (UL)                                  | Any shape of lesions with ulcer floor                                       |

| Therapeutic factors                                              | Description                                                                 |
|------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Clipping method (CLIP)                                           | Endoscopic hemostasis using a clip (EZ clip; Olympus, Tokyo, Japan)         |
| Electrocoagulation (EC)                                          | Electrocoagulation with single-use electrosurgical hemostatic forceps (Coagrasper; Olympus) and an electrosurgical generator (ESG-100; Olympus) |
| CLIP + EC                                                        | Hemostasis in combination with CLIP and EC                                  |
| Argon plasma coagulation (APC)                                   | Argon plasma coagulation is a non-contact coagulation technique using ionized argon gas (APC300/CC200; Erbe, Tuebingen, Germany) |
| Endoscopic band ligation (EBL)                                   | The bleeding point is pulled into the device, the elastic O-ring is released, and the bleeding point is tied with the ring (Pneumo-Activate EVL device; Sumitomo Bakelite, Tokyo, Japan) |
| Observation                                                      | Endoscopic hemostasis could not be performed because no exposed blood vessels were suspected of bleeding points or active bleeding. |

were receiving antithrombotic therapy, 53 had cardiac diseases, 39 had infections, 34 had diabetes mellitus, 30 were diagnosed with cerebrovascular disease, 26 were on dialysis, 22 had cancer, 19 had a fracture, 18 had hypoalbuminemia, and 14 were corticosteroid users (Figure 4). Eighty-seven patients (94%) exhibited multiple patient background factors. The median number of background factors per patient was 5 (IQR 3–6 factors).

### Lesion factors

Regarding the lesion type, ulcer floor-forming lesions were observed in 77 patients, and Dieulafoy lesions were observed in 16 patients. In addition, active bleeding occurred at the initial endoscopy in 40 patients (43%).

### Therapeutic factors

Hemostatic procedures were performed in 58 patients (62%) at the initial endoscopy. Of these patients, CLIP was employed in 31, EC in 15, CLIP with EC in eight, argon plasma coagulation in three, and endoscopic band ligation in one. No bleeding points were confirmed in the remaining 35 patients who had opted for observation, but rebleeding was observed in 11 patients (31.4%; Table 2). The results are summarized in the flowchart (Figure 5).

### Univariate analysis

In the univariate analysis, none of the background factors showed significant differences between the rebleeding and non-rebleeding groups. However, the number of patients with active bleeding at the initial endoscopy was significantly higher in the rebleeding group (rebleeding rate: 47.5% [19/40 patients], odds ratio [OR] 3.05, 95% confidence interval [CI] 1.16–8.36, $p = 0.015$). As for lesion types, the presence of Dieulafoy lesions and ulcer floor-forming lesions was not significantly different between both groups. The rebleeding rate after initial endoscopic hemostasis was lower...
### TABLE 2  Characteristics of the 11 patients with rebleeding of patients who had opted for observation at the first endoscopy

| Patient (age, sex) | Lesion type | Re-bleeding (times) | Treatment at the second endoscopy | Active bleeding after the second endoscopy | Prognosis (Cause of death) |
|-------------------|-------------|---------------------|----------------------------------|-------------------------------------------|--------------------------|
| 82, M             | UL          | 5                   | Observation                       | –                                         | Death (bleeding with AHRUS) |
| 81, F             | UL          | 1                   | Ad. Gauze Tampon                  | –                                         | Recovery                 |
| 63, M             | UL          | 5                   | CLIP                             | (+)                                       | Recovery                 |
| 61, M             | UL          | 1                   | EC                               | –                                         | Recovery                 |
| 82, F             | UL          | 1                   | EC                               | (+)                                       | Recovery                 |
| 79, F             | UL          | 5                   | EC                               | (+)                                       | Death (primary disease)  |
| 87, M             | UL          | 5                   | Observation                       | –                                         | Recovery                 |
| 64, F             | UL          | 1                   | Observation                       | –                                         | Recovery                 |
| 82, F             | UL+D        | 2                   | Observation                       | (+)                                       | Recovery                 |
| 80, M             | D           | 1                   | Observation                       | –                                         | Death (primary disease)  |
| 70, M             | UL          | 1                   | Observation                       | –                                         | Recovery                 |

Abbreviations: Ad. Gauze Tampon, treatment by stuffing gauze tampons soaked in diluted adrenaline solution into the anus to attempt pressure hemostasis; AHRUS, acute hemorrhagic rectal ulcer syndrome; CLIP, clipping; EC, electrocoagulation; D, Dieulafoy lesion; UL, Ulcer floor-forming lesion.

### FIGURE 4  Patient prevalence for each background factor

with CLIP (25.8%; 8/31 patients) than with EC (46.7%; 7/15 patients). However, both groups had no significant differences in therapeutic factors (Table 3).

### Multivariate analysis

In the multivariate analysis, active bleeding at the initial endoscopy had a significantly higher risk for rebleeding (OR 4.88, 95% CI 1.80–14.46, \( p = 0.003 \)). Conversely, hemostasis performed using CLIP at the initial endoscopy had a significantly lower risk for rebleeding (OR 0.30, 95% CI 0.09–0.88, \( p = 0.035 \); Table 4). The breakdown of treatment methods according to the presence or absence of active bleeding is summarized in Table 5.

### DISCUSSION

#### Underlying disease

Several studies have reported that AHRUS develops in bedridden patients with comorbidities.3–6,8,13,15,24 Nakamura et al. demonstrated via the laser-Doppler method that only patients with AHRUS had decreased lower rectal blood flow while in the supine position,3 which the clinical history of arteriosclerosis can explain.5,12,13

This study observed a median of five clinical background factors per patient. Frequently observed background factors were arteriosclerosis-related,5,12,13 such
## TABLE 3 Univariate analysis of the presence or absence of rebleeding in cases of acute hemorrhagic rectal ulcer syndrome

| Factors                     | Rebleeding (+) (n = 31) (%) | Rebleeding (–) (n = 62) (%) | Total (n = 93) (%) | Univariate OR (95% CI), p-value |
|-----------------------------|-----------------------------|-----------------------------|-------------------|--------------------------------|
| Age (median [IQR])          | 78 (58–82)                  | 79 (51–85)                  | 79 (51–83)        | 1.83 (0.32–19.20), 0.71        |
| **Clinical background factors** |                            |                             |                   |                                |
| Bedridden state             | 29 (93.4)                   | 55 (88.7)                   | 84 (90.3)         | 1.83 (0.32–19.20), 0.71        |
| Antithrombotic therapy      | 18 (58.1)                   | 35 (56.5)                   | 53 (57.0)         | 1.07 (0.41–2.82), 1.00         |
| Cardiac disease             | 18 (58.1)                   | 35 (56.5)                   | 53 (57.0)         | 1.07 (0.41–2.82), 1.00         |
| Male                        | 18 (58.1)                   | 32 (51.6)                   | 50 (53.8)         | 1.29 (0.50–3.42), 0.66         |
| Infection                   | 16 (51.6)                   | 23 (37.1)                   | 39 (41.9)         | 1.80 (0.69–4.74), 0.19         |
| Diabetes mellitus           | 11 (35.5)                   | 23 (37.1)                   | 34 (36.6)         | 0.93 (0.34–2.49), 1.00         |
| Cerebrovascular disease     | 09 (29.0)                   | 21 (33.9)                   | 30 (32.3)         | 0.80 (0.27–2.22), 0.81         |
| On dialysis                 | 10 (32.3)                   | 16 (25.8)                   | 26 (28.0)         | 1.36 (0.47–3.85), 0.62         |
| Cancer                      | 07 (22.6)                   | 15 (24.2)                   | 22 (23.7)         | 0.91 (0.28–2.79), 1.00         |
| Fracture                    | 05 (16.1)                   | 14 (22.6)                   | 19 (20.4)         | 0.66 (0.17–2.23), 0.59         |
| Hypoalbuminemia             | 06 (19.4)                   | 12 (19.4)                   | 18 (19.4)         | 1.00 (0.27–3.30), 1.00         |
| Corticosteroid usage        | 07 (22.6)                   | 7 (11.3)                    | 14 (15.1)         | 2.27 (0.61–8.53), 0.22         |
| **Lesion factors**          |                             |                             |                   |                                |
| Ulcer floor-forming lesion  | 25 (80.6)                   | 52 (83.9)                   | 77 (82.8)         | 0.80 (0.23–3.01), 0.77         |
| Dieulafoy lesion            | 06 (19.4)                   | 10 (16.1)                   | 16 (17.2)         | 1.24 (0.33–4.30), 0.77         |
| Active bleeding             | 19 (61.3)                   | 21 (33.9)                   | 40 (43.0)         | 3.05 (1.16–8.36), 0.015*       |
| **Therapeutic factors**     |                             |                             |                   |                                |
| CLIP                        | 08 (25.8)                   | 23 (37.1)                   | 31 (33.3)         | 0.59 (0.20–1.66), 0.35         |
| EC                          | 07(22.6)                    | 08 (12.9)                   | 15 (16.1)         | 1.95 (0.54–6.98), 0.25         |
| CLIP + EC                   | 03 (9.7)                    | 05 (8.1)                    | 08 (8.6)          | NE                             |
| APC                         | 02 (6.5)                    | 01 (1.6)                    | 03 (3.2)          | NE                             |
| EBL                         | 00 (0.0)                    | 01 (1.6)                    | 01 (1.1)          | NE                             |
| Observation                 | 11 (35.5)                   | 24 (38.7)                   | 35 (37.6)         | 0.87 (0.32–2.32), 0.82         |

**:* p < 0.05. **:** p < 0.01.

Abbreviations: 95% CI, 95% confidence interval; APC, argon plasma coagulation; CLIP: clipping; EBL, endoscopic band ligation; EC, electrocoagulation; IQR, interquartile range; NE, not evaluated; OR, odds ratio.

## TABLE 4 Multivariate analysis of the presence or absence of rebleeding in acute hemorrhagic rectal ulcer syndrome cases

| Factors                     | Rebleeding (+) (n = 31) (%) | Rebleeding (–) (n = 62) (%) | Total (n = 93) (%) | Multivariate OR (95% CI), p-value |
|-----------------------------|-----------------------------|-----------------------------|-------------------|--------------------------------|
| Active bleeding             | 19 (61.3)                   | 21 (33.9)                   | 40 (43.0)         | 4.88 (1.80–14.46), 0.003**      |
| CLIP                        | 08 (25.8)                   | 23 (37.1)                   | 31 (33.3)         | 0.30 (0.09–0.88), 0.035*        |

**:* p < 0.05. **:** p < 0.01.

Abbreviations: 95% CI, 95% confidence interval; CLIP: clipping; OR, odds ratio.

as antithrombotic therapy, cardiac disease, diabetes mellitus, cerebrovascular disease, on dialysis, and protracted wound healing factors including infection, diabetes mellitus, cancer, hypoalbuminemia, and corticosteroid usage. In older individuals with multiple comorbidities and poor general health, hypoperfusion of the lower rectum (due to arteriosclerosis and a bedridden state), arteriosclerosis-related factors, and protracted wound healing factors are expected to be closely related to AHRUS development.

In this study, the 30-day mortality rate was 15.0%. The direct cause of death in most AHRUS patients was not bleeding from AHRUS but rather their primary disease. In such cases, AHRUS is only one of the signs of death; it might be challenging to save the patients even if we succeeded in hemostasis. On the other hand, nearly
TABLE 5  Breakdown of therapeutic factors by active bleeding and rebleeding in acute hemorrhagic rectal ulcer syndrome

| [Active bleeding (+)] | Rebleeding (+) (n = 19) | Rebleeding (−) (n = 21) | Total (n = 40) |
|-----------------------|-------------------------|-------------------------|---------------|
| CLIP                  | 8                       | 13                      | 21            |
| EC                    | 5                       | 2                       | 7             |
| CLIP+EC               | 3                       | 5                       | 8             |
| APC                   | 2                       | 0                       | 2             |
| EBL                   | 0                       | 1                       | 1             |
| Observation           | 1                       | 0                       | 1             |

| [Active bleeding (−)] | Rebleeding (+) (n = 12) | Rebleeding (−) (n = 41) | Total (n = 53) |
|-----------------------|-------------------------|-------------------------|---------------|
| CLIP                  | 0                       | 10                      | 10            |
| EC                    | 2                       | 6                       | 8             |
| CLIP+EC               | 0                       | 0                       | 0             |
| APC                   | 0                       | 1                       | 1             |
| EBL                   | 0                       | 0                       | 0             |
| Observation           | 10                      | 24                      | 34            |

Abbreviations: CLIP, clipping; EC, electrocoagulation; APC, argon plasma coagulation; EBL, endoscopic band ligation.

80% of patients had successful endoscopic hemostasis and their general condition was restored.

Although further studies are needed to determine whether controlling rebleeding improves overall survival in AHRUS patients, preventing rebleeding with AHRUS, which is one of the factors that worsen patients’ general conditions, is crucial to recovery.

### Reasons for the high incidence of rebleeding

A high rate of rebleeding is critical in managing patients with AHRUS. The risk factors for rebleeding are under investigation, and no consensus has been reached in the literature. In this study, active bleeding during initial endoscopy was a significant risk factor for rebleeding, even when endoscopic hemostasis was successful. It is unclear why active bleeding at the first emergency endoscopy increases the risk of rebleeding. From our observations, plausible explanations could include poor healing of ulcers due to poor general health conditions, a larger diameter of the ruptured blood vessel, and arterial hemorrhage. One crucial observational finding in our study was the presence of bleeding from multiple vessels (Figure 6a) or the occurrence of rebleeding in an area other than the initial bleeding point.

Reportedly, circumferential-type ulcers are a risk factor for rebleeding, and it is plausible that bleeding points can frequently develop in a circumferential ulcer more than in a small ulcer. It is challenging to perform pretreatment in bedridden patients with poor general health conditions, especially those in shock. Moreover, it is difficult to establish a complete field of vision while aspirating residual stool and blood clots. Even in such a situation, the entire rectum, or as much as possible, should be observed, considering the possibility of multiple bleeding points. Since there was bleeding from the new ulcers, another measure to prevent rebleeding is fundamentally recovering the patients’ general conditions.

### Difficulties in identifying Dieulafoy lesions

Dieulafoy lesions are reportedly associated with a high rebleeding rate and are characterized by abnormally large, exposed vessels with small, shallow ulcers. However, because of the ambiguity in defining ulcer size, abnormal vascular lesions that do not form ulcers may be reported as Dieulafoy lesions. Therefore, we herein classified all lesions without ulceration as Dieulafoy lesions as it was difficult to distinguish between Dieulafoy and vascular lesions.

In our study, there was no significant difference in the rebleeding rates between Dieulafoy and floor-forming lesions. Based on our clinical experience, once a bleeding point can be identified, CLIP is effective for the hemostasis of the exposed bleeding duct in a Dieulafoy lesion as it is surrounded by normal mucosa. However, the problem is the difficulty in identifying Dieulafoy lesions. Thirty-five patients were observed without hemostasis as the bleeding point could not be identified at the initial endoscopy; 11 of these patients experienced rebleeding. At least four patients had active bleeding at the second or subsequent endoscopy; six of these could not note the bleeding point even at the second endoscopy; hemostatic treatment could not be performed (Table 2). In most of the 11 cases, ulcer lesions were found; however, since it was challenging
to identify the bleeding point even after multiple observations, we believe that bleeding may have occurred from an unidentified Dieulafoy lesion. Identifying elusive bleeding points is a severe issue that requires further investigation.

Endoscopic hemostasis

CLIP hemostasis methods induced significantly less rebleeding. Only the exposed blood vessel is gripped directly to stop the bleeding in CLIP; the destruction of the surrounding tissue is minimal. Contrarily, EC involves coagulation of the mucous membrane around the broken blood vessel, and the destruction of the surrounding tissue in EC is larger than that of CLIP. Therefore, the observed difference in rebleeding rates between the methods is reasonable as EC may have exacerbated the hypoperfusion of the rectal mucosa and delayed wound healing by damaging the tissue. However, since this is a retrospective observational study with a limited number of patients, treatment selection or patient background bias cannot be definitively excluded. The endoscopists’ skills may greatly influence CLIP. At the facility where the current study was conducted, at least two endoscopists oversaw all examinations. Hemostatic procedures were performed under the supervision of a senior physician, thus ensuring a certain level of quality was maintained. The provision of stable clipping techniques may be one factor contributing to this study’s low clipping rebleeding rate.

EC requires effective electrosurgical hemostats and an electrosurgical generator with appropriate power and effect settings to utilize the appropriate coagulation mode for the organ and situation. In this study, the settings of the electrosurgical generator were set at the endoscopist’s discretion. Furthermore, different modes of coagulation waves and types of hemostatic forceps may slightly reduce tissue damage.

CLIP had no significant difference in the univariate analysis, whereas it had a significant difference in the multivariate analysis; this is due to active bleeding, which showed a significant difference even in the univariate analysis and could be stopped by CLIP. Of the 40 patients with active bleeding at the initial endoscopy, the 21 who did not rebleed received various treatments (CLIP: 13, EC: 2, COM: 5, endoscopic band ligation: 1), with CLIP being the most common. Of the 53 patients with no active bleeding at the initial endoscopy, 10 had hemostasis with clips and no rebleeding (Table 5). In other words, clipping is effective regardless of the presence or absence of active bleeding. Therefore, endoscopists should avoid using EC and stop the bleeding with CLIP in patients with AHRUS.

Lesson learned case

One of the study participants experienced 14 episodes of rebleeding due to AHRUS (Figure 6b). Repeated hemostasis performed through EC induced scarring of the surrounding mucous membranes, resulting in an intractable ulcer. Thus, CLIP was used in place of EC. The ulcer healed over an extended period as the patient’s general condition improved. However, CLIP became difficult after scar tissue had formed, suggesting that the order in which treatment methods are selected is crucial.

Limitations

This study had some limitations. First, this was a single-center study with a limited number of patients. Second, the retrospective study design may have caused treatment selection and patient background biases. Third, the endoscopists’ skill and equipment quality may have affected the efficacy of endoscopic hemostasis and the
degree of tissue damage. Therefore, additional multi-center prospective studies with more cases would be desirable.

CONCLUSION

In bedridden older individuals with poor general health, multiple combinations of arteriosclerosis-related factors and protracted wound healing factors can induce AHRUS. We strongly recommend performing hemostasis via CLIP on suspected bleeding points, including active bleeding sites, in AHRUS.

CONFLICT OF INTEREST

None.

DATA AVAILABILITY STATEMENT

The data supporting this study’s findings are available on request from the corresponding author, Natsumi Uehara. However, the data are not publicly available as they could compromise the privacy of research participants.

ORCID

Natsumi Uehara https://orcid.org/0000-0001-5483-1916
Yuichiro Kuroki https://orcid.org/0000-0003-2087-8163
Misako Tohata https://orcid.org/0000-0003-2077-9683

REFERENCES

1. Kohno H, Katsumi M, Ura S et al. Two cases of acute massive bleeding from the rectal ulcer due to brain diseases. Nippon Daicho Komonbyo Gakkai Zasshi 1980; 33: 222–7. Japanese.
2. Hirooka T, Yuasa H, Itakura K et al. Acute hemorrhagic rectal ulcer – Special reference to its clinical findings. Gastroenterol Endosc 1984; 26: 1344–50. Japanese.
3. Nakamura S, Okawa K, Hara J et al. Etiology of acute hemorrhagic rectal ulcer laser Doppler analysis of rectal mucosal blood flow in lateral and horizontal supine position at bed rest. Gastroenterol Endosc 1996; 38: 1481–7. Japanese.
4. Takeuchi K, Tsuzuki Y, Ando T et al. Clinical characteristics of acute hemorrhagic rectal ulcer. J Clin Gastroenterol 2001; 33: 226–8.
5. Nakamura S, Okawa K, Hara J et al. Clinical studies on acute hemorrhagic rectal ulcers. Gastroenterol Endosc 1997; 39: 175–82. Japanese.
6. Oku T, Maeda M, Ihara H et al. Clinical and endoscopic features of acute hemorrhagic rectal ulcer. J Gastroenterol 2006; 41: 962–70.
7. Tseng CA, Chen LT, Tsai KB et al. Acute hemorrhagic rectal ulcer syndrome: A new clinical entity? Report of 19 cases and review of the literature. Dis Col Rectum 2004; 47: 895–903.
8. Hung HY, Changchien CR, You JF et al. Massive hematochezia from acute hemorrhagic rectal ulcer in patients with severe comorbid illness: Rapid control of bleeding by anal suturing of bleeder using anorectector. Dis Col Rectum 2006; 49: 238–43.
9. Peterman A, Harrison SK, Naylor AR, Donnelly PK. Benign rectal ulcer: A rare cause of life-threatening haemorrhage. Scott Med J 1993; 38: 48–9.
10. Yeoh KG, Kang JY. Dieulafoy’s lesion in the rectum. Gastrointest Endosc 1996; 43: 614–6.
11. Baxter M, Aly EH. Dieulafoy’s lesion: Current trends in diagnosis and management. Ann R Coll Surg Engl 2010; 92: 548–54.
12. Lin CK, Liang CC, Chang HT, Hung FM, Lee TH. Acute hemorrhagic rectal ulcer: An important cause of lower gastrointestinal bleeding in the critically ill patients. Dig Dis Sci 2011; 56: 3631–7.
13. Matsumoto T, Inokuma T. Clinical course and rebleeding predictors of acute haemorrhagic rectal ulcer: 5-year experience and review of the literature. Colorectal Dis 2013; 15: 878–84.
14. Nishimura N, Mizuno M, Shimodate Y, Doi A, Mouri H, Matsuoka K. Risk factors for recurrent bleeding from acute hemorrhagic rectal ulcer. Scand J Gastroenterol 2018; 53: 831–4.
15. Motomura Y, Akahoshi K, Matsu S et al. Clinical and endoscopic characteristics of acute haemorrhagic rectal ulcer, and endoscopic haemostatic treatment: A retrospective study of 95 patients. Colorectal Dis 2010; 12: e320–5.
16. Jung JH, Kim JW, Lee HW et al. Acute hemorrhagic rectal ulcer syndrome: Comparison with non-hemorrhagic rectal ulcer lower gastrointestinal bleeding. J Dig Dis 2017; 18: 521–8.
17. Yamamoto H, Nagayama K, Wakiya I et al. Clinical study in seventeen cases of acute hemorrhagic rectal ulcer. Gastroenterol Endosc 1991; 33: 2052–61. Japanese.
18. Fujimaki E, Sugawara M, Inoue Y et al. Endoscopic findings and clinical features of acute hemorrhagic rectal ulcers. Gastroenterol Endosc 1993; 35: 2421–4. Japanese.
19. Hokama A, Kishimoto K, Kinjo F, Fujita J. Endoscopic clipping in the lower gastrointestinal tract. World J Gastrointest Endosc 2009; 1: 7–11.
20. ASGE Technology Committee, Conway JD, Adler DG et al. Endoscopic hemostatic devices. Gastrointest Endosc 2009; 69: 987–96.
21. Li YR, Hsu PI, Wang HM et al. Comparison of hemostatic efficacy of argon plasma coagulation with and without distilled water injection in treating high-risk bleeding ulcers. Biomed Res Int 2014; 2014: 413095.
22. Ishii N, Setoyama T, Deshpande GA et al. Endoscopic band ligation for colonic diverticular hemorrhage. Gastrointest Endosc 2012; 75: 382–7.
23. Yamada A, Nikura R, Yoshida S, Hirata Y, Koike K. Endoscopic management of colonic diverticular bleeding. Dig Endosc 2015; 27: 720–5.
24. Kagawa K, Matsuoka K, Kinugasa H et al. Clinical endoscopic hemorrhagic rectal ulcer. Gastroenterol Endosc 2012; 54: 3124–30. Japanese.
25. Powers JG, Higham C, Broussard K, Phillips TJ. Wound healing and treating wounds: Chronic wound care and management. J Am Acad Dermatol 2016; 74: 607–25.